Hartmut M Hanauske-Abel

Title: Hartmut M Hanauske-Abel: Innovator in mRNA Decay Research

Introduction

Hartmut M Hanauske-Abel is a prominent inventor based in Edgewater, NJ (US). He has made significant contributions to the field of molecular biology, particularly in the area of mRNA decay. With a total of 10 patents, his work has advanced our understanding of gene expression and its regulation.

Latest Patents

Hanauske-Abel's latest patents include innovative methods for treating Nonsense-Mediated Decay (NMD). One notable patent is titled "Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A." This patent provides methods for treating patients suffering from NMD by administering an inhibitor of NMD and a nonsense suppressor. This approach decreases the degradation of NMD susceptible mRNA and blocks translation termination at misplaced nonsense codons. Another significant patent is the "Method of inhibiting nonsense-mediated mRNA decay," which outlines methods for treating NMD by administering a composition that includes an eIF5A inhibitor compound. This method effectively prevents intracellular hypusination of eIF5A, thereby increasing gene expression of NMD-susceptible mRNA.

Career Highlights

Throughout his career, Hanauske-Abel has worked with esteemed institutions such as Cornell Research Foundation Inc. and Rutgers, the State University of New Jersey. His research has been pivotal in developing therapeutic strategies for genetic disorders related to mRNA decay.

Collaborations

Hanauske-Abel has collaborated with notable colleagues, including Robert Walter Grady and Timothy A McCaffrey. These collaborations have further enriched his research and contributed to advancements in the field.

Conclusion

Hartmut M Hanauske-Abel's innovative work in mRNA decay research has led to significant advancements in understanding gene expression. His contributions continue to influence the field and pave the way for future therapeutic developments.